المؤلفون: R.H.M. Verheijen, de Truuske Bock, T.M. Mooij, Katja N. Gaarenstroom, Marian J.E. Mourits, M. van Beurden, C.T.M. Brekelmans, Matti A. Rookus, R. I. Olivier, H. van Boven, Leon F.A.G. Massuger, J.A. de Hullu, B. B. J. Hermsen, Curt W. Burger

المساهمون: Obstetrics & Gynecology, Medical Oncology, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Life Course Epidemiology (LCE)

المصدر: British Journal of Cancer, 96(9), 1335-1342. Nature Publishing Group
British Journal of Cancer, 96, 1335-42
British Jounal of Cancer, 96(9), 1335-1342. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 96, 9, pp. 1335-42

مصطلحات موضوعية: HIGH-RISK WOMEN, Cancer Research, Time Factors, FAMILIAL OVARIAN-CANCER, Observation, Aetiology, screening and detection [ONCOL 5], TVU, PROPHYLACTIC SURGERY, Ovarian carcinoma, Clinical Studies, Mass Screening, Stage (cooking), ULTRASOUND, Ovarian Neoplasms, BRCA1 Protein, Obstetrics, Medical record, ONSET BREAST-CANCER, Middle Aged, Oncology, Carrier State, Female, EARLY-STAGE, Adult, medicine.medical_specialty, CA125, Translational research [ONCOL 3], SURVEILLANCE, medicine, Humans, SALPINGO-OOPHORECTOMY, Mass screening, Neoplasm Staging, BRCA2 Protein, Gynecology, Hereditary cancer and cancer-related syndromes [ONCOL 1], business.industry, screening, Reproducibility of Results, Immunotherapy, gene therapy and transplantation [UMCN 1.4], BRCA1, medicine.disease, BRCA2, Annual Screening, Confidence interval, ovarian carcinoma, PREVENTIVE SURGERY, FALLOPIAN-TUBE, Standardized mortality ratio, CA-125 Antigen, Mutation, CAI25, Ovarian cancer, business, Follow-Up Studies

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a05c7b26bf3c2ce20fe81ac2362e3c
https://hdl.handle.net/1765/35422